Intussusception incidence among infants in the UK and Republic of Ireland: A pre-rotavirus vaccine prospective surveillance study

Samad, Lamiya; Cortina‐Borja, Mario; Bashir, Haitham El; Sutcliffe, Alastair; Marven, Sean; Cameron, J. Claire; Lynn, Richard; Taylor, Brent

doi:10.1016/j.vaccine.2013.06.084

Cited by 39 publications

(35 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The higher rate in NL could be due to chance in this small provincial sample, differences in coding and reporting practices in NL, or genuinely higher incidence. Regional variation has been observed in other countries 17 . Further study including primary data collection would be necessary to verify and confirm the reasons for these higher rates.…”

Section: Discussionmentioning

confidence: 91%

Assessing the risk of intussusception and rotavirus vaccine safety in Canada

Hawken

Ducharme

Rosella

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: Intussusception has been identified as a rare adverse event following rotavirus immunization. We sought to determine the incidence of intussusception among infants in Canada both before and after introduction of rotavirus immunization programs. Methods: We used Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD) to identify infants under 1 y of age who were admitted to a Canadian hospital, which the exception of Quebec, which does not submit data to CIHI, with a diagnosis of intussusception (ICD-10 code K56.1, and ICD-9 code 560) between January 1st, 2003 and December 31, 2013. We compared rates of intussusception hospitalization before and after rotavirus vaccine program introduction. Rates were adjusted for calendar year, age (in months), sex and region using Poisson regression models. Denominator data for infants under 1 year, stratified by age in months, were obtained from Statistics Canada. Results: Annual intussusception hospitalization rates ranged from 20-30 per 100,000 infants over the study period, with no evidence of a trend over time. Intussusception hospitalization rates were highest in infants 4 to <8 months and lowest in those under 2 months or between 10 and <12 months. Males had higher rates than females both overall and within each age group. The rate of intussusception hospitalization after rotavirus vaccine program introduction was 22.4 (95% CI: 18.3, 27.4) compared to 23.4 (95% CI: 21.5, 25.4) per 100,000 before program introduction. Conclusions: We have described baseline intussusception hospitalization rates for infants in Canada and have found no evidence of a change in rate after implementation of routine rotavirus immunization programs.

show abstract

Section: Discussionmentioning

confidence: 91%

Assessing the risk of intussusception and rotavirus vaccine safety in Canada

Hawken

Ducharme

Rosella

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…However, the epidemiological data on the risk of IS is limited in Asian countries where RV vaccination is expected to be introduced soon . In base line studies conducted in Europe and America, IS cases reported are less than 60 per 100 000 as compared with higher rates in Oceania including far east where >60 to 302/100 000 cases are reported and lower rates (<30/100 000) in Southeast and Central Asian countries …”

Section: Strategies To Control Rv Infectionmentioning

confidence: 99%

“…12.6 | RV vaccine and IS However, the epidemiological data on the risk of IS is limited in Asian countries where RV vaccination is expected to be introduced soon 143. In base line studies conducted in Europe and America, IS cases reported are less than 60 per 100 000 as compared with higher rates in Oceania including far east where >60 to 302/100 000 cases are reported and lower rates (<30/100 000) in Southeast and Central Asian countries 144. After introduction of rhesus reassortant tetravalent vaccineRotashield (RRV-TV; Wyeth Vaccines) in United States in the late 19th century, almost 30-fold risk of IS was observed 145,146.…”

mentioning

confidence: 99%

Rotavirus: Genetics, pathogenesis and vaccine advances

Sadiq

Bostan

Yinda

et al. 2018

Reviews in Medical Virology

110

View full text Add to dashboard Cite

Since its discovery 40 years ago, rotavirus (RV) is considered to be a major cause of infant and childhood morbidity and mortality particularly in developing countries. Nearly every child in the world under 5 years of age is at the risk of RV infection. It is estimated that 90% of RV-associated mortalities occur in developing countries of Africa and Asia. Two live oral vaccines, RotaTeq (RV5, Merck) and Rotarix (RV1, GlaxoSmithKline) have been successfully deployed to scale down the disease burden in Europe and America, but they are less effective in Africa and Asia. In April 2009, the World Health Organization recommended the inclusion of RV vaccination in national immunization programs of all countries with great emphasis in developing countries. To date, 86 countries have included RV vaccines into their national immunization programs including 41 Global Alliance for Vaccines and Immunization eligible countries. The predominant RV genotypes circulating all over the world are G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8], while G12[P6] and G12[P8] are emerging genotypes. On account of the segmented genome, RV shows an enormous genetic diversity that leads to the evolution of new genotypes that can influence the efficacy of current vaccines. The current need is for a global RV surveillance program to monitor the prevalence and antigenic variability of new genotypes to formulate future vaccine development planning. In this review, we will summarize the previous and recent insights into RV structure, classification, and epidemiology and current status of RV vaccination around the globe and will also cover the status of RV research and vaccine policy in Pakistan.

show abstract

“…It is important to examine hernial orifices for signs of an incarcerated inguinal hernia and to consider volvulus secondary to malrotation, but the most common cause of intestinal obstruction in infants aged 3 months to 6 years is intussusception. The incidence of intussusception in the United Kingdom is 24.8/100 000 live births, 3 and the peak age of presentation is 4-7 months, although it can occur outside this age range. 4 The classic triad of redcurrant jelly stool, abdominal pain, and vomiting are the most familiar presenting symptoms of intussusception quoted by medical students.…”

Section: Long Answermentioning

confidence: 99%